NL-OMON48552已完成不适用
Response assessment of post-transplant lymphoproliferative disorder with 18F-FDG-PET/CT and minimal residual disease monitoring, a multicenter multinational feasibility study - Minimal residual disease monitoring in PTLD
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Patients having undergone a solid organ transplantation or hematopoietic stem
- •cell transplantation.
- •- Histologically proven CD20+ monomorphic PTLD (with or without EBV association)
- •- Age > 18 years
- •- Intent to treat patient according to standard protocol (rituximab / R-CHOP).
- •Clinicians are allowed to adapt protocol in the best interest of the patient
- •- Measurable disease on 18F-FDG-PET/CT at diagnosis
- •-Patient*s written informed consent and written consent for data collection.
排除标准
- •-A complete surgical resection of tumor.
- •-Upfront treatment with external beam radiation therapy.
- •-Known to be HIV positive.
研究者
相似试验
尚未招募
不适用
Minimal residual disease monitoring in PTLDCirculating tumor DNA Post-transplant lymphoproliferative disorder18F-flurodeoxyglucose positron emission tomography/computed tomography Minimal residual diseaseNL-OMON22796niversity Medical Center Groningen30
进行中（未招募）
不适用
Treatment of patients with post-transplant lymphoproliferative disorder (PILD) with a sequential treatment consisting of anti-CD20 antibody rituximab and CHOP + GCSF chemotherapy (including first, second and third amendment).EUCTR2005-000743-29-BEHeads Study Group
进行中（未招募）
不适用
PTLD: Multicentric Retrospective StudyPTLDNCT06422715Fondazione Italiana Linfomi - ETS241
终止
2 期
Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)Post-transplantation Lymphoproliferative DisorderNCT01458548Charite University, Berlin, Germany70
已完成
2 期
Risk Stratified Sequential Treatment for CD20-positive PTLDPosttransplant Lymphoproliferative DisorderPTLDNCT00590447Charite University, Berlin, Germany152